Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct-acting antivirals

about

Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct-acting antivirals

Item

http://www.wikidata.org/entity/Q58378595

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2017

@uk

name

Liver stiffness measurement pr ...... with direct-acting antivirals

@en

Liver stiffness measurement pr ...... with direct-acting antivirals

@nl

type

Item

label

Liver stiffness measurement pr ...... with direct-acting antivirals

@en

Liver stiffness measurement pr ...... with direct-acting antivirals

@nl

prefLabel

Liver stiffness measurement pr ...... with direct-acting antivirals

@en

Liver stiffness measurement pr ...... with direct-acting antivirals

@nl

P1476

Liver stiffness measurement pr ...... with direct-acting antivirals

@en

P2093

Hidemi Goto

http://www.w3.org/2001/XMLSchema#string

Masatoshi Ishigami

http://www.w3.org/2001/XMLSchema#string

Takanori Hirai

http://www.w3.org/2001/XMLSchema#string

Takashi Honda

http://www.w3.org/2001/XMLSchema#string

Teiji Kuzuya

http://www.w3.org/2001/XMLSchema#string

Yuko Kojima

http://www.w3.org/2001/XMLSchema#string

P2860

Preliminary study of two antiviral agents for hepatitis C genotype 1.

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis.

Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.

Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.

Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.

α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.

Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.

Risk of Hepatocellular Cancer in HCV Patients Treated With Direct Acting Antiviral Agents.

Liver stiffness reduction correlates with histological characteristics of hepatitis C patients with sustained virological response.

P304

44-49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JGH3.12007

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yoji Ishizu

Kazuhiko Hayashi

Yoshihiko Tachi

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30483532

http://www.w3.org/2001/XMLSchema#string

P932

6207000

http://www.w3.org/2001/XMLSchema#string